05:53 AM EDT, 07/14/2026 (MT Newswires) -- Merck KGaA (MRK.F) said Tuesday the European Commission approved the expanded use of Erbitux, or cetuximab, for patients with BRAF V600E-mutant metastatic colorectal cancer. The approval allows Erbitux to be used as a first-line treatment in combination with encorafenib and the FOLFOX chemotherapy regimen. The German science and technology company said the regulatory nod was based on the phase 3 Breakwater clinical trial results, which showed improvements in response rates, progression-free survival, and overall survival compared with standard chemotherapy.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.